Subcutaneous administration of brain natriuretic peptide in experimental heart failure

Horng Haur Chen, J. Aaron Grantham, John A. Schirger, Michihisa Jougasaki, Margaret May Redfield, John C Jr. Burnett

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

OBJECTIVES: The objective of this investigation was to define for the first time the cardiorenal and humoral actions of repeated short-term administration of subcutaneous (SQ) brain natriuretic peptide (BNP) administration during the evolution of experimental heart failure. BACKGROUND: The rationale of this study was based on BNP as a vasodilating, natriuretic, renin-inhibiting and lusitropic peptide of cardiac origin. METHODS: First, we defined the cardiorenal and humoral responses to acute low and high dose (5 μg/kg or 25 μg/kg) of SQ BNP in experimental heart failure to establish the acute efficacy of an SQ delivery. Second, we characterized the response to 10 days of repeated short-term administration of BNP during the evolution of experimental heart failure produced by rapid ventricular pacing. RESULTS: Plasma BNP and 3',5'-cyclic guanosine monophosphate rapidly increased and peaked at 30 min after acute SQ BNP administration with increases in urinary sodium excretion, urine flow and renal blood flow in association with reductions in cardiac filling pressures. After 10 days of repeated short-term administration of SQ BNP, cardiac output was increased and systemic vascular resistance and pulmonary capillary wedge pressure were decreased, as compared with untreated dogs with heart failure. CONCLUSIONS: This study demonstrated for the first time that repeated short-term administration of SQ BNP administration for 10 days during the evolution of left ventricular dysfunction in a canine model results in an improvement in cardiovascular hemodynamics. This investigation supports a potential novel strategy for the chronic administration of BNP in the therapeutics of heart failure. (C) 2000 by the American College of Cardiology.

Original languageEnglish (US)
Pages (from-to)1706-1712
Number of pages7
JournalJournal of the American College of Cardiology
Volume36
Issue number5
DOIs
StatePublished - Nov 1 2000

Fingerprint

Brain Natriuretic Peptide
Heart Failure
Pulmonary Wedge Pressure
Renal Circulation
Cyclic GMP
Left Ventricular Dysfunction
Renin
Cardiac Output
Vascular Resistance
Canidae
Hemodynamics
Sodium
Urine
Dogs
Pressure
Peptides

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Subcutaneous administration of brain natriuretic peptide in experimental heart failure. / Chen, Horng Haur; Grantham, J. Aaron; Schirger, John A.; Jougasaki, Michihisa; Redfield, Margaret May; Burnett, John C Jr.

In: Journal of the American College of Cardiology, Vol. 36, No. 5, 01.11.2000, p. 1706-1712.

Research output: Contribution to journalArticle

@article{b34361271f744264945e5ce0ac5427de,
title = "Subcutaneous administration of brain natriuretic peptide in experimental heart failure",
abstract = "OBJECTIVES: The objective of this investigation was to define for the first time the cardiorenal and humoral actions of repeated short-term administration of subcutaneous (SQ) brain natriuretic peptide (BNP) administration during the evolution of experimental heart failure. BACKGROUND: The rationale of this study was based on BNP as a vasodilating, natriuretic, renin-inhibiting and lusitropic peptide of cardiac origin. METHODS: First, we defined the cardiorenal and humoral responses to acute low and high dose (5 μg/kg or 25 μg/kg) of SQ BNP in experimental heart failure to establish the acute efficacy of an SQ delivery. Second, we characterized the response to 10 days of repeated short-term administration of BNP during the evolution of experimental heart failure produced by rapid ventricular pacing. RESULTS: Plasma BNP and 3',5'-cyclic guanosine monophosphate rapidly increased and peaked at 30 min after acute SQ BNP administration with increases in urinary sodium excretion, urine flow and renal blood flow in association with reductions in cardiac filling pressures. After 10 days of repeated short-term administration of SQ BNP, cardiac output was increased and systemic vascular resistance and pulmonary capillary wedge pressure were decreased, as compared with untreated dogs with heart failure. CONCLUSIONS: This study demonstrated for the first time that repeated short-term administration of SQ BNP administration for 10 days during the evolution of left ventricular dysfunction in a canine model results in an improvement in cardiovascular hemodynamics. This investigation supports a potential novel strategy for the chronic administration of BNP in the therapeutics of heart failure. (C) 2000 by the American College of Cardiology.",
author = "Chen, {Horng Haur} and Grantham, {J. Aaron} and Schirger, {John A.} and Michihisa Jougasaki and Redfield, {Margaret May} and Burnett, {John C Jr.}",
year = "2000",
month = "11",
day = "1",
doi = "10.1016/S0735-1097(00)00911-6",
language = "English (US)",
volume = "36",
pages = "1706--1712",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Subcutaneous administration of brain natriuretic peptide in experimental heart failure

AU - Chen, Horng Haur

AU - Grantham, J. Aaron

AU - Schirger, John A.

AU - Jougasaki, Michihisa

AU - Redfield, Margaret May

AU - Burnett, John C Jr.

PY - 2000/11/1

Y1 - 2000/11/1

N2 - OBJECTIVES: The objective of this investigation was to define for the first time the cardiorenal and humoral actions of repeated short-term administration of subcutaneous (SQ) brain natriuretic peptide (BNP) administration during the evolution of experimental heart failure. BACKGROUND: The rationale of this study was based on BNP as a vasodilating, natriuretic, renin-inhibiting and lusitropic peptide of cardiac origin. METHODS: First, we defined the cardiorenal and humoral responses to acute low and high dose (5 μg/kg or 25 μg/kg) of SQ BNP in experimental heart failure to establish the acute efficacy of an SQ delivery. Second, we characterized the response to 10 days of repeated short-term administration of BNP during the evolution of experimental heart failure produced by rapid ventricular pacing. RESULTS: Plasma BNP and 3',5'-cyclic guanosine monophosphate rapidly increased and peaked at 30 min after acute SQ BNP administration with increases in urinary sodium excretion, urine flow and renal blood flow in association with reductions in cardiac filling pressures. After 10 days of repeated short-term administration of SQ BNP, cardiac output was increased and systemic vascular resistance and pulmonary capillary wedge pressure were decreased, as compared with untreated dogs with heart failure. CONCLUSIONS: This study demonstrated for the first time that repeated short-term administration of SQ BNP administration for 10 days during the evolution of left ventricular dysfunction in a canine model results in an improvement in cardiovascular hemodynamics. This investigation supports a potential novel strategy for the chronic administration of BNP in the therapeutics of heart failure. (C) 2000 by the American College of Cardiology.

AB - OBJECTIVES: The objective of this investigation was to define for the first time the cardiorenal and humoral actions of repeated short-term administration of subcutaneous (SQ) brain natriuretic peptide (BNP) administration during the evolution of experimental heart failure. BACKGROUND: The rationale of this study was based on BNP as a vasodilating, natriuretic, renin-inhibiting and lusitropic peptide of cardiac origin. METHODS: First, we defined the cardiorenal and humoral responses to acute low and high dose (5 μg/kg or 25 μg/kg) of SQ BNP in experimental heart failure to establish the acute efficacy of an SQ delivery. Second, we characterized the response to 10 days of repeated short-term administration of BNP during the evolution of experimental heart failure produced by rapid ventricular pacing. RESULTS: Plasma BNP and 3',5'-cyclic guanosine monophosphate rapidly increased and peaked at 30 min after acute SQ BNP administration with increases in urinary sodium excretion, urine flow and renal blood flow in association with reductions in cardiac filling pressures. After 10 days of repeated short-term administration of SQ BNP, cardiac output was increased and systemic vascular resistance and pulmonary capillary wedge pressure were decreased, as compared with untreated dogs with heart failure. CONCLUSIONS: This study demonstrated for the first time that repeated short-term administration of SQ BNP administration for 10 days during the evolution of left ventricular dysfunction in a canine model results in an improvement in cardiovascular hemodynamics. This investigation supports a potential novel strategy for the chronic administration of BNP in the therapeutics of heart failure. (C) 2000 by the American College of Cardiology.

UR - http://www.scopus.com/inward/record.url?scp=0034332775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034332775&partnerID=8YFLogxK

U2 - 10.1016/S0735-1097(00)00911-6

DO - 10.1016/S0735-1097(00)00911-6

M3 - Article

C2 - 11079680

AN - SCOPUS:0034332775

VL - 36

SP - 1706

EP - 1712

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 5

ER -